Preview

Medicine and ecology

Advanced search

ETHNIC FEATURES OF HER2NEW POSITIVE IMMUNOHISTOCHEMICAL PHENOTYPE OF BREAST CANCER

Abstract

Breast cancer is a malignant tumor of the glandular tissue of the breast. According to IARC, 167,114 new cases of breast cancer are registered in the world annually. In the structure of oncological pathology, this localization takes first place for many years. 10-12% of the world's total is breast cancer out of ten million new cases of malignant diseases. According to research in the US, the incidence of breast cancer is steadily increasing in older women, namely after the onset of menopause. These age-specific morbidity rates are higher in Caucasian women than afroamericans. Although the mortality rates from breast cancer in black women are higher. In Kazakhstan breast cancer takes the first place among other cancers in women. Unfortunately, the incidence rate is increasing year by year. There are differences in the incidence of breast cancer among diverse ethnic groups, this is associated with the traditions and way of life of various peoples. The issue of racial differences in patients with breast cancer (BC) has recently become more topical. In the era of individualization of treatment, knowledge of ethnic characteristics, such as tumor aggressiveness, its immunohistochemical characteristics in representatives of different nationalities, seems necessary and logical. A conducted literary search has shown that that question is more covered only in the United States of America (USA). The similar studies are not available or they are of a single character with a small sample of patients in Europe, Asia, Africa, South America.

About the Authors

Ya. L. Poluektova
Karaganda state medical university
Kazakhstan


N. A. Kabildina
Karaganda state medical university
Kazakhstan


V. B. Sirota
Karaganda state medical university
Kazakhstan


B. .. Sapar
Karaganda state medical university
Kazakhstan


References

1. Заридзе Д. Г. Эпидемиология и скрининг рака молочной железы //Вопросник онкологии. - 2002. - Т. 48, №4-5. - С. 489-495.

2. Кулигина Е. Ш. Иммуногистохимия рака молочной железы. - М., 2011. - С. 25-28.

3. Показатели онкологической службы Республики Казахстан за 2013 год /К. Ш. Нургазиев, Д. М. Байпеисов, Г. Т. Сейсенбаева и др. - Алматы, 2014. - 104 с.

4. Райхман Я. Национальные традиции образа жизни и риск возникновения рака // www.all-about-cancerprevention.com/nac_1.html

5. Шубин В. П. Молекулярно -генетический анализ особенностей структуры и экспрессии генов BRCA1/2 при раке яичников и молочной железы: Автореф. дис..канд. биол. наук. - М., 2011. - С. 18-19.

6. An overview of prognostic factors for long-term survivors of breast cancer /I. Soerjomataram, M. W. Louwman, J. G. Ribot et al. //Breast Cancer Res. Treat. - 2008. - V. 107, №3. - P. 309-323.

7. Breast cancer in Nigeria and Finland: epidemiological, clinical and histological comparison /O. F. Ikpatt, T. Kuopio, R. Ndoma-Egba, Y. Collan //Anticancer. Res. - 2002. - V. 22, №5. -Pp. 3005-3012.

8. Breast carcinoma tumor characteristics in black and white women /J. G. Elmore, V. M. Moceri, D. Carter, E. B. Larson //Cancer. - 1998. - V. 83, №12. - P. 2509-2515.

9. Clinicopathologic significance of the basal -like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes /M. J. Kim, J. Y. Ro, S. H. Ahn et al. //Hum. Pathol. - 2006. - V. 37, №9. - Pp. 1217-1226.

10. ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study /S. Bianchi, D. Palli, M. Falchetti et al. /J. Cell Physiol. - 2006. - V. 206, №3. - Pp. 702-708.

11. Estimates of worldwide burden of cancer in 2008 /J. Ferlay, H. R. Shin, F. Bray, D. Forman et al. //Int. J. Cancer - 2010. - V. 127. - Pp. 2893-2917.

12. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance /G. Arpino, H. Weiss, A. V. Lee et al. //J. Natl. Cancer Inst. - 2005. - V. 7, №97. - Pp. 1254-1261.

13. Ethnicity and breast cancer: factors influencing differences in incidence and outcome / R. T. Chlebowski, Z. Chen, G. L. Anderson et al. // J. Natl. Cancer. Inst. - 2005. - V. 97, №6. - P. 439-448.

14. Expression of cerbB2 protein and its relation to prognosis in 284 primary breast cancer patients /L. F. Yang, S. T. Song, X. B. Li et al. // Zhonghua Zhong Liu Za Zhi. - 2006. - V. 28, №4. - P. 294-297.

15. Fejerman L. Population differences in breast cancer severity /L. Fejerman, E. Ziv // Pharmacogenomics. - 2008. - V. 9, №3. - Pp. 323-333.

16. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information /L. Ryden, G. Landberg, O. Stal et al. //Breast Cancer Res. Treat. - 2008. - V. 109, №2. - P. 351-357.

17. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13 239 cases /S. M. Gapstur, J. Dupuis, P. Gann et al. //Cancer. - 1996. -V. 77, №8. - P. 1465-1471.

18. Jatoi I. Qualitative age interactions in breast cancer studies : a minireview /I. Jatoi, W. F. Anderson //Future Oncol. - 2010. - V. 6. - Pp. 1781-1788.

19. Joslyn S. A. Hormone receptors in breast cancer: racial differences in distribution and survival //Breast Cancer Res. Treat. - 2002. -V. 73, №1. - P. 45-59.

20. Li C. I. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older /C. I. Li, K. E. Malone, J. R. Daling //Cancer Epidemiol. Biomarkers Prev. - 2002. - V. 11, №7. - Pp. 601-607.

21. Li C. I. Differences in breast cancer stage, treatment, and survival by race and ethnicity /C. I. Li, K. E. Malone, J. R. Daling //Arch. Intern. Med. - 2003. - V. 163, №1. - P. 49-56.

22. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer /M. Martin, A. Rodriguez-Lescure, A. Ruiz et al. // Breast Cancer Res. Treat. - 2010. - V. 123. - Pp. 149-157.

23. Parker J. S. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial //J. Clin. Oncol. - 2009. -V. 27. - Pp. 1168-1176.

24. Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu / A. T. Stark, S. Claud, A. Kapke et al. //Cancer. - 2005. - V. 104, №10. - Pp. 2189-2196.

25. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma /P. L. Porter, M. J. Lund, M. G. Lin et al. // Cancer. - 2004. - V. 100. - P. 2533-2542.

26. Reis-Filho J. S. Triple negative tumours: a critical review /J. S. Reis-Filho, A. N. J. Tutt // Histopathology. - 2008. - V. 52. - Pp. 108-118.

27. The protective role of pregnancy in breast cancer /J. Russo, R. Moral, G. A. Balogh et al. //Breast Cancer Res. - 2011. - V. 7. - Pp. 131 -142.

28. Trends in breast cancer by race and ethnicity: update 2006 /C. Smigal, A. Jemal, E. Ward et al. //CA Cancer J. Clin. - 2006. - V. 56, №3. - P. 168-183.

29. Tumor markers in breast cancer- European Group on Tumor Markers recommendations /R. Molina, V. Barak, A. van Dalen et al. // Tumour Biology. - 2015. - V. 26, №6. - Pp. 281293.


Review

For citations:


Poluektova Ya.L., Kabildina N.A., Sirota V.B., Sapar B... ETHNIC FEATURES OF HER2NEW POSITIVE IMMUNOHISTOCHEMICAL PHENOTYPE OF BREAST CANCER. Medicine and ecology. 2018;(1):29-35. (In Russ.)

Views: 202


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2305-6045 (Print)
ISSN 2305-6053 (Online)